LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Dovitinib | 10.0 | uM | LJP5 | 3 | E19 | 72 | hr | 1097 | 1352 | 3769 | 0.3587 | 0.0953 |
| BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 1 | D13 | 72 | hr | 1097 | 3823 | 3769 | 1.0142 | 1.0200 |
| BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 2 | D13 | 72 | hr | 1097 | 4498 | 3769 | 1.1932 | 1.2726 |
| BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 3 | D13 | 72 | hr | 1097 | 4613 | 3769 | 1.2238 | 1.3156 |
| BT-20 | Erlotinib | 10.0 | uM | LJP5 | 1 | M19 | 72 | hr | 1097 | 2638 | 3769 | 0.6998 | 0.5766 |
| BT-20 | Erlotinib | 10.0 | uM | LJP5 | 2 | M19 | 72 | hr | 1097 | 2710 | 3769 | 0.7189 | 0.6035 |
| BT-20 | Erlotinib | 10.0 | uM | LJP5 | 3 | M19 | 72 | hr | 1097 | 2437 | 3769 | 0.6465 | 0.5014 |
| BT-20 | Foretinib | 10.0 | uM | LJP5 | 1 | H07 | 72 | hr | 1097 | 943 | 3769 | 0.2502 | -0.0577 |
| BT-20 | Foretinib | 10.0 | uM | LJP5 | 2 | H07 | 72 | hr | 1097 | 978 | 3769 | 0.2595 | -0.0446 |
| BT-20 | Foretinib | 10.0 | uM | LJP5 | 3 | H07 | 72 | hr | 1097 | 1008 | 3769 | 0.2674 | -0.0334 |
| BT-20 | R406 | 10.0 | uM | LJP6 | 1 | C13 | 72 | hr | 1097 | 1698 | 3769 | 0.4505 | 0.2248 |
| BT-20 | R406 | 10.0 | uM | LJP6 | 2 | C13 | 72 | hr | 1097 | 1740 | 3769 | 0.4616 | 0.2405 |
| BT-20 | R406 | 10.0 | uM | LJP6 | 3 | C13 | 72 | hr | 1097 | 1512 | 3769 | 0.4011 | 0.1552 |
| BT-20 | Pictilisib | 10.0 | uM | LJP6 | 1 | D19 | 72 | hr | 1097 | 797 | 3769 | 0.2114 | -0.1124 |
| BT-20 | Pictilisib | 10.0 | uM | LJP6 | 2 | D19 | 72 | hr | 1097 | 955 | 3769 | 0.2534 | -0.0532 |
| BT-20 | Pictilisib | 10.0 | uM | LJP6 | 3 | D19 | 72 | hr | 1097 | 915 | 3769 | 0.2427 | -0.0682 |
| BT-20 | Gefitinib | 10.0 | uM | LJP6 | 1 | N07 | 72 | hr | 1097 | 2689 | 3769 | 0.7134 | 0.5957 |
| BT-20 | Gefitinib | 10.0 | uM | LJP6 | 2 | N07 | 72 | hr | 1097 | 2450 | 3769 | 0.6500 | 0.5062 |
| BT-20 | Gefitinib | 10.0 | uM | LJP6 | 3 | N07 | 72 | hr | 1097 | 2782 | 3769 | 0.7380 | 0.6305 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 1 | O01 | 72 | hr | 1097 | 341 | 3769 | 0.0905 | -0.2830 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 2 | O01 | 72 | hr | 1097 | 613 | 3769 | 0.1626 | -0.1812 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 3 | O01 | 72 | hr | 1097 | 933 | 3769 | 0.2475 | -0.0615 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 1 | O01 | 72 | hr | 1097 | 585 | 3769 | 0.1552 | -0.1917 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 2 | O01 | 72 | hr | 1097 | 667 | 3769 | 0.1769 | -0.1610 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 3 | O01 | 72 | hr | 1097 | 562 | 3769 | 0.1491 | -0.2003 |